Pfizer/BioNTech says its Covid-19 vaccine is 100% effective and well tolerated in adolescents

Clinical trial results of Pfizer/BioNTech's Covid-19 vaccine showed its efficacy is 100% and it is well tolerated in youths ages 12 to 15, the companies said...

Posted: Mar 31, 2021 9:09 AM

Clinical trial results of Pfizer/BioNTech's Covid-19 vaccine showed its efficacy is 100% and it is well tolerated in youths ages 12 to 15, the companies said Wednesday.

Pfizer/BioNTech plan to submit the data to the US Food and Drug Administration as soon as possible for expanded emergency use authorization of the two-dose vaccine.

In a Phase 3 trial of 2,260 participants ages 12 to 15 in the US, the vaccine elicited strong antibody responses one month after the second dose -- exceeding those demonstrated in people ages 16 to 25 in previous trials, Pfizer reported. The vaccine is currently authorized in the US for emergency use in people 16 and older.

Researchers observed 18 Covid-19 cases among the 1,129 participants who were given a placebo, and none among the 1,131 volunteers who got the vaccine. The data has yet to be peer reviewed.

Pfizer/BioNTech added that the side effects seen in the young teens were similar to those seen among 16 to 25-year-olds. Common side effects include pain at the injection site, fatigue and fever. The participants will be monitored for protection and safety for two years after their second dose.

Those comparisons to the older population are important, because researchers are building off of the knowledge they gained in the adult trials.

Researchers can define a number of antibodies that are a correlate of the protection seen in adults, and then look for that level of antibodies in pediatric participants to know that the vaccine is providing protection. That's why the Covid-19 vaccine trials in children and adolescents have generally required fewer volunteers than the adult trials.

"We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15," said Pfizer CEO Albert Bourla. "We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year."

Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children's Hospital, said on CNN's New Day Wednesday, said schools can open without vaccinating students, but vaccines will help.

"I think it's likely a green light to move forward, to move down in terms of vaccinating adolescents 12 to 15," Hotez said, noting that the vaccine will still need to be evaluated for authorization in that age group.

"The bottom line is that by the fall I think there's a good possibility we'll be vaccinating teenagers, 12 and up, and for middle schools, junior high schools, high schools, it's really good news in the United States for both teachers and staff. We'll have teachers and staff vaccinated, we'll have the students vaccinated in those middle schools and high schools."

A return to the classroom isn't the only factor at play. Health experts have emphasized the importance of protecting as many people as possible through vaccination, as more infectious Covid-19 variants continue to spread throughout the nation.

"We all long for a normal life. This is especially true for our children," said BioNTech CEO Ugur Sahin. "The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant."

Pfizer recently told CNN that the safety demonstrated in this adolescent trial helped the company make the decision to begin testing its vaccine in younger children.

A separate Phase 1/2/3 study of the Pfizer/BioNTech vaccine in children ages 6 months to 11 years launched last week, when the first children ages 5 to 11 received a shot. Pfizer/BioNTech plans to begin dosing 2 to 5-year-olds next week and work its way down to participants ages 6 months to 2 years. The company aims to enroll 4,644 children in the trial and expects results by the end of 2021.

Moderna is also testing its vaccine in adolescents and children, in two clinical trials of children ages 12 to 17 and those ages 6 months to 11 years.

Experts anticipate Covid-19 vaccines won't be available for children 11 and younger in time for the upcoming school year. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said those younger children may have to wait until the first quarter of 2022.

Dr. Buddy Creech, director of Vanderbilt University's Vaccine Research Program and an investigator in Moderna's pediatric trials, estimates a Covid-19 vaccine could be available for high-risk kids 12 and older by July or August, but likely won't be available for children 11 and younger until November or December, at the earliest.

Oregon Coronavirus Cases

Data is updated nightly.

Cases: 173626

Reported Deaths: 2457
CountyCasesDeaths
Multnomah34641566
Washington23309229
Marion20037299
Clackamas15216204
Lane11478144
Jackson9846127
Umatilla795383
Deschutes698772
Linn410763
Yamhill407074
Malheur342558
Polk341752
Klamath340859
Josephine304262
Douglas302765
Benton272518
Jefferson205932
Coos196631
Columbia153326
Union141124
Lincoln129720
Wasco128628
Hood River112429
Morrow107815
Clatsop8838
Crook86819
Baker85114
Curry5919
Tillamook5763
Lake4137
Grant4044
Harney3046
Wallowa1575
Sherman570
Gilliam551
Wheeler251
Unassigned00

California Coronavirus Cases

Data is updated nightly.

Cases: 3714587

Reported Deaths: 60922
CountyCasesDeaths
Los Angeles122811823601
Riverside2972154525
San Bernardino2944644544
San Diego2745663662
Orange2687624886
Santa Clara1167722013
Kern1077641317
Sacramento1010581646
Fresno1004311642
Alameda850891475
Ventura802301000
San Joaquin714311334
Contra Costa66839781
Stanislaus603061028
Tulare49383829
Monterey43260352
San Mateo41050560
San Francisco35947517
Santa Barbara33830446
Solano31875239
Merced31196452
Sonoma29632311
Imperial27920718
Kings22755245
Placer21751283
San Luis Obispo20917256
Madera16234239
Santa Cruz15554203
Marin13851226
Yolo13547199
Shasta11677217
Butte11529196
El Dorado9688109
Napa965479
Sutter9268109
Yuba609844
San Benito596963
Lassen566624
Tehama543056
Nevada444775
Tuolumne406664
Mendocino398747
Amador361646
Humboldt358737
Lake339943
Glenn235425
Colusa219216
Calaveras205551
Siskiyou194021
Inyo141738
Del Norte12747
Mono12734
Plumas6906
Modoc4884
Mariposa4197
Trinity3985
Sierra1100
Alpine880
Unassigned610
Medford
Partly Cloudy
69° wxIcon
Hi: 78° Lo: 39°
Feels Like: 69°
Brookings
Partly Cloudy
45° wxIcon
Hi: 73° Lo: 45°
Feels Like: 45°
Medford
Clear
69° wxIcon
Hi: 55° Lo: 27°
Feels Like: 69°
Medford
Partly Cloudy
69° wxIcon
Hi: 81° Lo: 38°
Feels Like: 69°
Klamath Falls
Clear
53° wxIcon
Hi: 65° Lo: 33°
Feels Like: 53°
Very warm Sunday
KDRV Radar
KDRV Fire Danger
KDRV Weather Cam

Community Events